CERo Therapeutics, Inc. presents preclinical data demonstrating that CER-1236 kills ovarian cancer cell lines without toxicity

Data presented as a poster at the SITC 2024 conference

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) — CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T-cell therapeutics that utilize phagocytic mechanisms, announces the presentation of preclinical data demonstrating the killing ability of its lead compound CER-1236 of ovaries demonstrate cancer cells in preclinical models with no evidence of toxicity in animal models. The data were presented in a poster at the Society for Immunology of Cancer (SITC) 2024 conference, held November 6-10, 2024 in Houston.

Interim CEO Chris Ehrlich commented: “We have long believed that CER-1236 has applications in multiple types of cancer. As we wait for the opportunity to introduce our compound into the AML clinic, we continue to see other models that are useful and minimal to non-toxic. These data are of particular interest as the company plans to apply for orphan designation in clinical development in due course. Regardless, these data are further confirmation that our approach has enormous potential to overcome some of the limitations of current chemotherapy approaches.”

In the study titled “TIM-4 expression in ovarian cancer samples can be targeted without toxicity by engineered chimeric engulfment receptor T cells,” researchers examined CER-1236 on the immune receptor TIM-4-L in ovarian cancer cell lines. The results showed that after the introduction of CER-1236 into these cell lines, TIM-4-L increased, which then responded by killing the cancer cells, but no toxicity to healthy cells was observed. The study also demonstrated the specificity of CER-1236 toward TIM-L-4, which the researchers concluded, combined with the lack of association with clinically relevant toxicity, could make the compound an attractive option for the treatment of ovarian cancer.

About CERo Therapeutics, Inc.
CERo is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which allows it to integrate certain desirable properties of both innate and adaptive immunity into a single therapeutic construct, is designed to harness the body’s entire immune repertoire to deliver optimized cancer therapy to reach. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by incorporating engulfment pathways that utilize phagocytic mechanisms to destroy cancer cells, creating what CERo calls chimeric engulfment Receptor T cells (“CER-T”). CERo believes that the differentiated activity of CER-T cells will allow them to have greater therapeutic application than the currently approved chimeric antigen receptor cell therapy (“CAR-T”), as the use of CER-T potentially addresses both hematologic malignancies and solid malignancies May include tumors. CERo expects to begin clinical trials for its lead product candidate CER-1236 for the treatment of hematologic malignancies in early 2025.

The story continues